Mankind Pharma is set to list on May 9 with a premium of Rs 120 apiece according to grey market trends. The company is valued at a price-to-earnings ratio of 30 times FY22 earnings and has a market capitalisation of Rs 44,000 crore. The initial share sale of the company was subscribed 15.32 times with strong interest from QIBs and is the largest IPO so far this year. The company has 25 manufacturing facilities across India, a dedicated in-house R&D centre and a team of over 600 scientists.
Post tariff tantrum, where could we see some positive surprises in Q1? Pashupati Advani explains
Pashupati Advani of Global Foray anticipates positive surprises in companies with lower tariffs and those leveraging arbitrage opportunities. He discusses the implications of tariff uncertainty
April 3, 2025